Effect of pea collagen peptide on glucose and lipid metabolism in patients with type 2 diabetes mellitus

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100042409

Enrollment

Unknown

Registered

2021-01-21

Start date

2021-02-18

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

Experimental group: Pea collagen peptide:Take pea collagen peptide orally at lunch and dinner, one bag each time, twice a day

Placebo group: Pea collagen:Take placebo orally at lunch and dinner, one bag each time, twice a day

Short-term experimental group: Pea collagen peptide:Take 1 bag of pea collagen peptide with breakfast

Short-term Placebo group:Take 1 bag of placebo with breakfast

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The age of patients >= 18 years old is not limited to men and women; 2. Patients diagnosed with type 2 diabetes mellitus; 3. Subjects in good health can move autonomously; 4. The subjects who could eat independently had enough food intake; 5. Subjects who did not use insulin; 6. Subjects with glycosylated hemoglobin 6.5-9.0% and fasting blood glucose < 10mmol / L; 7. Subjects with triglyceride < 4.5mmol/l; 8. Subjects who did not use hypoglycemic drugs or used two or less oral hypoglycemic drugs; 9. Subjects without mental illness.

Exclusion criteria

Exclusion criteria: 1. Subjects who have increased / decreased more than 30% of their eating energy in recent 3 months; 2. Patients with DKA or other acute complications of diabetes in recent 3 months; 3. Patients with severe diseases in recent 3 months, such as severe infection, surgery, mental system diseases, etc; 4. Pregnant or lactating subjects; 5. Patients with liver and kidney dysfunction (transaminase more than 2 times the upper limit of normal reference range, ckdg3a or above); 6. Subjects who were previously intolerant or allergic to peptide nutrition.

Design outcomes

Primary

Measure	Time frame
Fasting blood glucose, insulin, C-peptide and insulin-like growth factor-1 (GLP-1);Postprandial blood glucose, insulin, C-peptide levels and insulin-like growth factor-1 (GLP-1) at 30, 60, 90, 120, 180 and 240 minutes;Detection of body composition;physical examination;Survey of dietary behavior;Visual analogue scale;	—

Countries

China

Contacts

Public ContactCheng Gaiping

West China Hospital of Sichuan University

656394130@qq.com+86 13982019705

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026